CEO Update - 27 November 2023

Last week felt like an important milestone for the UK life science sector. As I sat in the Life Science Council in No 10 Downing Street with new Government Ministers, leaders of public institutions like the MHRA and global CEOs, I reflected that no other country in the world is putting together a working collaborative life science group like this.

It’s one of the many reasons why I’m confident about our ongoing journey to make the UK the best place in the world to start, scale and develop world-leading life science businesses. A tough, but long-term deal has been made on medicines pricing access and growth for the UK has been negotiated and agreed by the ABPI  (now called VPAG), and the Chancellor’s Autumn statement moved the dial on many agendas central to our sector. If you didn’t join the webinar explaining the details you can watch the recording and read Martin’s excellent blog for sector-specific insight but the highlights were:

N10 Steve pics - life science council with members.jpg

 

N10 Steve pics - life science council.jpg

 

  • £520 million in capital grants available for medicine manufacturing that will enable the UK to compete to be the home for next-generation technologies like mRNA and CRISPR;
  • Implementing structural changes in the UK pensions landscape, including reforms to boost investment, allocating £50 million to the Future Fund: Breakthrough, and introducing a VC Fellowship scheme to train the next generation of investors;
  • Decreasing the threshold for R&D intensive tax credit company scheme from 40% to 30% will be particularly helpful for scaling clinical-stage biotech firms – clear guidance from HMRC is now critical to make this operational;
  • The spin-out review will increase the pace, quality and timeliness of startups from UK universities;
  • New investment zones demonstrating the importance of life sciences to the economy across the country.

None of this would, I believe, have made it into the government’s agenda without the sustained work and expert input of BIA members working through your Association – so congratulations and thank you for all the hard work and support.

The Autumn Statement gives our sector forward momentum as well as practical agendas and projects to build on in the months ahead. I said at the Life Science Council that the investors of the world’s wallets are watching what is happening in the UK – the proof of the pudding will be seen in the months ahead.

It was great to join our Government Affairs Network last week for a great evening discussing all things Westminster, it was a privilege to hear stories for 37 years at the coalface from David Boyd, Senior Advisor on UK Government Affairs for AstraZeneca. He reminded us that we all are privileged to work in the sector and hopefully make a difference. He was certainly clear that how the sector engages with politicians has professionalised and changed for the better over his career.  Thanks to all who came for an enjoyable evening.

Next week NICE is holding a webinar for BIA members on their refreshed NICE Advice service, which aims to provide a more flexible and easier-to-access industry support service. The webinar will provide an opportunity for BIA members to hear directly from NICE about the service, ask questions and provide feedback. The webinar will take place on 4 December from 11 am to 12:30 pm. To register, please email [email protected].

I’m really looking forward to seeing many of you at bioProcess UK in Brighton this week – a fantastic lineup and great networking ahead.

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

CEO Update - 20 February 2024

I'm looking forward to the BIA Committee Summit this week. It will be great to see 200 members in Westminster at one of the most lively and insightful events we do each year. I know it's the volunteer expert army that gives the BIA its unique impact with government and it's always great to understand the committee's priorities and the ideas at the intersection between committees that arise from the event.

Beyond health: why BIA is championing the biorevolution 

The BIA has named this frontier of science Deep Biotech. Our brand-new report, "Deep Biotech: Disruptive innovation for global sustainability" highlights how deep biotech is key to creating a sustainable UK bioeconomy and making the UK a science superpower that benefits all. 

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

Recent decision from the EPO smooths the way to obtaining patents in Europe

The BIA’s Intellectual Property Advisory Committee (IPAC) helps BIA understand and shape the environment for IP ownership to ensure strong protection for BIA member companies. Our EU policy subcommittee has taken a look at what a recent European decision means for the right to claim priority to an earlier filed patent application. This blog sets out some of the details of the case, and the practical implications for BIA members.​​​​​​​

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

CEO Update - 12 February 2024

It was great to see the hugely positive response we’ve had to the launch of our new report "Deep Biotech: Disruptive innovation for global sustainability". I believe we're on the cusp of a biorevolution powered by Deep Biotech, and I want our Association at the forefront of shaping the future of Deep Biotech and championing its disruptive potential.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Enter the dragon: Exploring China’s life sciences market

Next week, Chinese people across the world will be celebrating Chinese New Year. This is the “year of the dragon”, a symbol of strength for the Chinese people. It also represents prosperity, a value Chinese strive for across aspects of life, society and business.

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

More within